Virtus Biotech Clinical Trials ETF
BBC
19 hedge funds and large institutions have $18.2M invested in Virtus Biotech Clinical Trials ETF in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
68% more capital invested
Capital invested by funds: $10.8M → $18.2M (+$7.37M)
27% more funds holding
Funds holding: 15 → 19 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.28% less ownership
Funds ownership: 38.91% → 36.63% (-2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$1.85M |
| 2 |
LPL Financial
San Diego,
California
|
+$498K |
| 3 |
Morgan Stanley
New York
|
+$482K |
| 4 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
+$363K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.15M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$31.3K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$7K |
| 4 |
FCM
Firestone Capital Management
Coral Gables,
Florida
|
-$1K |
BBC Hedge Fund Activity: Q2 2020 in Review
19 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2020, worth a combined $18.2M — up 68% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BBC positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Fulcrum Equity Management, opening a new position worth an estimated $1.85M. The largest seller was Royal Bank of Canada, cutting an estimated $2.15M.
- 19 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2020, up from 15 in Q1 2020.
- Funds reported $18.2M of Virtus Biotech Clinical Trials ETF stock for Q2 2020, up 68% quarter-over-quarter.
- 6 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2020 and 2 closed out, a net change of +4 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2020 was Fulcrum Equity Management, an estimated $1.85M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2020 was Royal Bank of Canada, an estimated $2.15M sold.
Based on aggregated 13F filings for Q2 2020.